Neurocrine Biosciences Inc.

NBIX | NASDAQ

Price Alert Chart Builder DCF Calculator

$144.12

-$2.11 (-1.44%)

Sep 21, 2026, 12:36 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.44%

(1D)

Rating

Updated: Sep 19, 2026

79.7

Fundamentals Excellent

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $14.49B

1D Range

143.92 146.23

52W Range

122.14 186.12

Valuation (TTM)

PE 21.44

PB 3.68

EV/EBITDA 15.65

Valuation (NTM)

Forward PE 15.63

Forward PEG 0.54

Price Target $203.82

Cash Flow

FCF Yield 5.9%

SBC Adj. FCF Yield 4.3%

SBC Impact -26.9%

Margins

Gross Margin 98.0%

Operating Margin 23.3%

FCF Margin 25.8%

Growth (CAGR)

Revenue 3Y | 5Y 26.3% | 26.7%

Dil EPS 3Y | 5Y 58.0% | 12.9%

FCF 3Y | 5Y 45.8% | 28.8%

Returns

ROA 13.2%

ROE 21.1%

ROIC 13.2%

Financial Health

Net Debt

$12M

Current Ratio 1.87

Interest Coverage 272.03

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric condi...

Sector Healthcare

Industry Biotechnology

Employees 2,500

IPO Date May 22, 1996

Website www.neurocrine.com

Fiscal Year January - December

Full Company Profile

Latest News

4 days ago · defenseworld.net

Corient Private Wealth LP Buys 9,645 Shares of Neurocrine Biosciences, Inc. $NBIX

Corient Private Wealth LP increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 21.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,680 shares of the company's stock after purchasing an additional 9,645 shares during

5 days ago · seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

11 days ago · seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

12 days ago · seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

19 days ago · prnewswire.com

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.

27 days ago · zacks.com

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.

29 days ago · defenseworld.net

B. Metzler seel. Sohn & Co. AG Acquires New Shares in Neurocrine Biosciences, Inc. $NBIX

B. Metzler seel. Sohn and Co. AG acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 5,986 shares of the company's stock, valued at approximately $1,009,000. Other institutional investors and hedge

1 month ago · zacks.com

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?

NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.

1 month ago · zacks.com

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?

Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.